Abstract 1983
Background
3rd-generation EGFR-TKI, OSIME showed a remarkable efficacy for T790M+ NSCLC. Moreover, OSIME has proven superior progression-free survival (PFS) over 1st-generation EGFR-TKIs in front-line setting, and it will be widely used in front-line and later settings. Various resistant mechanisms were reported: C797S (cis/trans); EGFR uncommon mutations such as E709K and L844V; T790M- conversion; HER2-amp; MET-amp; PIK3CA/BRAF mutations; and histological transformation such as small cell and EMT. AFA is an irreversible EGFR-TKI with a potency as pan-HER inhibitor. Preclinical and clinical studies showed high sensitivity to EGFR uncommon mutations. Preclinical studies also showed a synergistic effect of AFA and BEV after acquired resistance (AR) to EGFR-TKIs. Our previously-conducted phase II study found a promising efficacy of AFA+BEV after AR: response rate (RR), 18.8%; disease control rate (DCR), 90.7%; and median PFS (mPFS), 6.3 months. Notably, preclinical data has suggested EGFR-TKI+BEV combination could overcome MET-associated resistance. Based on the above background, we hypothesize several resistant mechanisms (e.g., C797S (trans), uncommon EGFR mutations, and HER2) to OSIME are sensitive to AFA, and synergism of additional BEV maximizes AFA sensitivity.
Trial design
This ABCD-study is a phase II study conducted by HANSHIN Oncology Group. ECOG PS 0-1 patients with EGFR-mutant NSCLC are enrolled after failure of OSIME. Liquid/histological rebiopsies before enrollment after OSIME failure are essential to examine the resistant mechanisms. Liquid /histological samples are analyzed to confirm gene mutations/fusions and copy-number gain using next-generation sequencers. AFA is prescribed at 30-40 mg QD, and BEV is administered at 15 mg/kg tri-weekly until progression. The primary endpoint is PFS. Sample size of 26 is based on a null mPFS of 4.0 months, an alternative mPFS of 6.0 months, power of 80% and one-sided 15% of type I error. We plan an exploratory analysis regarding differential efficacies according to each resistant mechanism.
Clinical trial identification
UMIN000030545.
Legal entity responsible for the study
The authors.
Funding
Boehringer Ingelheim.
Editorial Acknowledgement
We thank Mr. David Martin for English editing.
Disclosure
A. Hata: Lecture fee: Boehringer Ingelheim; Financially support analysis of liquid/histological samples: Boehringer Ingelheim. N. Katakami: Honoraria and Research fund: Boehringer Ingelheim. K. Nishino, T. Kurata, M. Tachihara, H. Daga, T. Kijima, S. Morita, K. Nishio, M. Satouchi: Honoraria: Boehringer Ingelheim. All other authors have declared no conflicts of interest.
Resources from the same session
5877 - TCR beta chain convergence defines the tumor infiltrating T cell repertoire of melanoma and non-small cell lung carcinoma.
Presenter: Timothy Looney
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3212 - PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors
Presenter: Ahmad Awada
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3574 - Pan-squamous genomic profiling stratified by anatomic tumor site and viral association
Presenter: Meagan Montesion
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4113 - Toward the Standardization of Bioinformatics Methods for the Accurate Assessment of Tumor Mutational Burden (TMB)
Presenter: Han Chang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4468 - Prediction of primary resistance to anti-PD1 therapy (APD1) in 2nd line NSCLC
Presenter: Egbert Smit
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4570 - Immunomodulatory germline variation impacts the development of multiple primary melanoma (MPM).
Presenter: Robert Ferguson
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1169 - Leukocyte telomere length and recurrence risk after EGFR-TKIs therapy in patients with advanced lung adenocarcinoma
Presenter: Ming Yang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1707 - Gene embedding: a novel machine learning approach to identify gene candidates related to immunotherapy responsiveness
Presenter: Chi Tung Choy
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2123 - Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials
Presenter: Ayman Madi
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5671 - The landscape of NTRK fusions in Chinese solid tumor patients
Presenter: Qi Ling
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract